Crape Jasmine: Analgesic and Anti-Inflammatory Claims, Conolidine and Beyond

Two entirely different stories hide under “crape jasmine relieves pain,” and almost every popular account of this plant merges them. One is about conolidine, a trace bark alkaloid that had to be chemically synthesised before anyone could study it, acting through a genuinely novel non-opioid mechanism discovered in a 2021 top-tier journal paper — real science about a molecule, not a plant a person can prepare. The other is about what the whole flower and leaf extract actually does in a rat’s paw or abdomen, which is also real, considerably less famous, works partly through the very opioid receptors conolidine’s fame rests on not needing, and has never been anywhere near a human trial. This page keeps the two apart and gives each its own accounting.

Table of Contents

  1. What Is Actually Being Claimed
  2. The Conolidine Story, Precisely
  3. The ACKR3/CXCR7 Mechanism, a Decade Later
  4. The Whole-Extract Data: A Separate Dataset
  5. Which Alkaloids Are Actually Responsible
  6. Gastroprotective and Anti-Ulcer Data
  7. Older Anti-Inflammatory and Sedative Data
  8. A Four-Species Comparison, and a Toxicity Number
  9. The Mechanism Ceiling
  10. Regulatory Status: There Is None
  11. What Would Actually Settle This
  12. Evidence Ledger for This Page
  13. Practical Guidance
  14. Key Research Papers
  15. Connections

What Is Actually Being Claimed

Three separate claims, each needing different evidence:

  1. Conolidine is a breakthrough non-opioid painkiller. True of the synthesised molecule in rodent models. Says nothing about the plant, because the plant cannot supply a usable amount of it.
  2. Crape jasmine extract (leaf, flower, whole plant) relieves pain. A separate, real, but much less discussed rodent finding, working through different and better-characterised alkaloids.
  3. Crape jasmine reduces inflammation. Supported by both the extract-level analgesia work and a dedicated gastroprotection study, plus one classic 1996 paper — real animal data, no human data, no dose.

The Conolidine Story, Precisely

Conolidine is a structurally unusual alkaloid present in only trace quantities in crape jasmine bark — so little that it could not be studied by direct extraction from the plant. In 2011, a chemistry team led by Glenn Micalizio published a concise total synthesis of conolidine in Nature Chemistry, working with pharmacologist Laura Bohn’s group to test the synthesised compound in rodent models of tonic and persistent pain. It produced meaningful analgesia. Critically, it did not appear to act through the classical mu, delta or kappa opioid receptors — the receptors morphine, oxycodone and every other conventional opioid analgesic use, along with essentially all of their liabilities: tolerance, dependence, constipation, and respiratory depression. A potent analgesic working through a different route is one of the most sought-after findings in modern pain pharmacology, which is why this one paper is still cited more than a decade later.

For roughly ten years after that, conolidine’s actual molecular target was unknown — an uncomfortable position for any promising drug lead, since a mechanism is usually what lets a discovery move toward an actual medicine.

Back to Table of Contents

The ACKR3/CXCR7 Mechanism, a Decade Later

In 2021, a European research group publishing in Signal Transduction and Targeted Therapy identified conolidine’s likely target: ACKR3, also called CXCR7, an atypical chemokine receptor that functions less like a conventional signalling receptor and more like a molecular scavenger — it soaks up and clears the body’s own naturally produced opioid peptides (enkephalins and related molecules) from circulation. Conolidine appears to block that scavenging function. The proposed consequence is elegant: instead of flooding opioid receptors with an external drug, blocking the scavenger allows the body’s own opioid peptides to accumulate and act for longer at their normal receptors — a way of amplifying the body’s own pain-control system rather than substituting for it. A 2021 clinical-facing review in Anesthesiology and Pain Medicine situated this discovery explicitly within the context of the opioid prescribing crisis, describing conolidine as a potential “beginning of a new era” in chronic pain management while being careful to note that further mechanistic and efficacy work remains necessary.

What none of this changes: conolidine still cannot be obtained in a pharmacologically meaningful amount from the plant itself. This is drug-discovery science about a synthesised small molecule and a specific human receptor, at a preclinical stage, with no clinical trial of conolidine itself yet reported. It is a genuine scientific achievement traceable back to this plant’s bark. It is not a reason to consume any preparation of the plant.

Back to Table of Contents

The Whole-Extract Data: A Separate Dataset

Here is the finding that gets lost whenever the conolidine story dominates the conversation: a completely separate line of research has tested crape jasmine’s whole flower extract — not purified conolidine, not a synthesised molecule — directly in standard rodent pain models, and found real activity.

A 2018 study in Food and Chemical Toxicology gave a methanolic extract of crape jasmine flowers to mice at three oral doses (125, 250 and 500 mg/kg) and tested it in two classic pain-screening assays: acetic-acid-induced abdominal writhing and formalin-induced paw licking. The extract produced measurable anti-nociception in both. The researchers then investigated the mechanism using standard pharmacological probe compounds: naloxone (an opioid receptor blocker), L-arginine, glibenclamide (which blocks potassium-ATP channels), and glutamate as an inducer, with morphine, L-NAME, methylene blue and aspirin as reference standards. The extract’s pain-relieving effect was significantly reduced by naloxone — meaning that at least part of it works through the same classical opioid receptors that morphine acts on. It was also reduced by L-arginine and glibenclamide pretreatment, and it inhibited pain triggered by glutamate, pointing to nitric-oxide and potassium-ATP-channel mechanisms operating alongside the opioid one. Co-administration with methylene blue produced no additional effect, arguing against a cyclic-GMP pathway.

Why this matters for how the conolidine headline gets read. The whole-extract effect is not simply “more of the same non-opioid mechanism conolidine uses.” Part of it is naloxone-reversible — classically opioid — which is the exact category conolidine’s fame rests on avoiding. A reader who takes “crape jasmine contains a novel non-opioid painkiller” and extends it to “so the whole plant is a safe non-opioid alternative” has the mechanism backwards for at least part of what the plant extract actually does. An uncharacterised plant preparation with partly opioid-receptor-mediated activity, at an unknown and unstandardised dose, is not a safer proposition than a conventional opioid — it may simply be an unmeasured one.

Back to Table of Contents

Which Alkaloids Are Actually Responsible

The 2018 flower-extract study did not stop at the pharmacology — it isolated the active constituents chemically, identifying three indole alkaloids from the anti-nociceptive fraction: voacangine, catharanthine, and O-acetyl vallesamine. Naming them precisely matters, because two of the three carry real chemotaxonomic and safety context worth stating plainly.

Back to Table of Contents

Gastroprotective and Anti-Ulcer Data

A companion 2013 study from an overlapping research group tested the same crape jasmine flower methanolic extract against chemically induced gastric ulcers in rats — aspirin- and ethanol-induced — at the same three oral doses (125, 250, 500 mg/kg), benchmarked against misoprostol, a real prostaglandin-analogue ulcer drug used as the positive control. The extract produced a dose-dependent gastroprotective effect: reduced ulcer index, reduced markers of oxidative damage (malondialdehyde), and increased levels of protective factors (catalase, superoxide dismutase, mucin, and non-protein sulfhydryls). The higher doses performed better than the lower ones. Mass spectrometry of the crude extract suggested the presence of several known indole alkaloids, though the paper’s own HPLC profiling underscored how chemically complex the whole extract actually is.

This is a real, dose-responsive animal finding using a validated ulcer model and a legitimate drug comparator — one of the more methodologically careful studies in this plant’s literature. It remains a single study, rat-only, with the same absence of any human data that runs through every claim on this page.

Older Anti-Inflammatory and Sedative Data

A 1996 Brazilian study, working under the plant’s older synonym Ervatamia coronaria, gave aqueous and alcoholic extracts to rats before a standard carrageenin-induced paw-inflammation test and found a significant anti-inflammatory effect from both routes of administration. The alcoholic extract additionally showed analgesic activity in the same animals and extended pentobarbital-induced sleeping time — a classic, if crude, marker of central nervous system depressant activity, worth flagging because it is a third distinct pharmacological effect (sedation) turning up incidentally in an analgesia-focused study, and a reminder that whole-plant extracts routinely do more than one thing to the nervous system at once.

Zooming out to the genus and family level confirms this is not an isolated, cherry-picked result. A 2021 review of Tabernaemontana species’ bioactive alkaloids names analgesic and anti-inflammatory activity among the recurring, independently reported properties across the genus, and a 2018 review of the wider Apocynaceae family reaches the same conclusion for the family as a whole — useful as corroborating context for why this specific plant keeps producing positive rodent pain and inflammation findings across independent laboratories, though neither review substitutes for species-specific human data, which remains absent either way.

Back to Table of Contents

A Four-Species Comparison, and a Toxicity Number

A useful corrective to any temptation to treat crape jasmine as an exceptionally powerful analgesic plant comes from a 2012 Bangladeshi study that tested four different traditional plants side by side in the same acetic-acid writhing assay: Acorus calamus (sweet flag), Kigelia pinnata (sausage tree), Mangifera indica (mango) and crape jasmine. At the higher of two tested doses, crape jasmine leaf extract produced 33.93% writhing protection — the weakest result of the four plants tested at that dose; Acorus calamus root reached 54.51%. The same paper ran a brine-shrimp lethality assay as a preliminary toxicity screen on all four extracts, reporting an LC₅₀ (the concentration lethal to half the test organisms) of 200 µg/mL for crape jasmine specifically. That number describes toxicity to brine shrimp larvae in a laboratory dish, a standard rough screening assay, not a human-relevant safe or unsafe dose — this page will not extrapolate it into one, and no dose figure for crape jasmine appears anywhere in this Benefits leg for that reason.

Back to Table of Contents

The Mechanism Ceiling

It is worth being explicit about what a best-case outcome for this plant’s pain-relief story would actually look like, because the two mechanisms involved already have known ceilings from approved drugs. The whole-extract anti-nociceptive effect is partly classical-opioid, meaning its best-case ceiling is bounded by everything already known about opioid analgesics: real pain relief, real tolerance and dependence risk with sustained use, and a well-characterised overdose danger — none of which becomes safer for being delivered by an unstandardised plant extract instead of a manufactured tablet. The anti-inflammatory and gastroprotective data point toward antioxidant and mucosal-protective mechanisms with a different, generally gentler ceiling, closer to what over-the-counter gastroprotective and anti-inflammatory approaches already offer. Conolidine’s ACKR3/CXCR7 mechanism is the one genuine exception to a mechanism-ceiling argument, precisely because it is new enough that no approved drug yet defines its ceiling — which is exactly why it remains a research finding about a molecule and not a reason to use the plant that happens to contain a trace of it.

Regulatory Status: There Is None

It is worth stating plainly what does not exist alongside what does. Herbs with a genuine, if imperfect, evidence base for a specific traditional use sometimes carry a formal regulatory acknowledgement short of full drug approval — the European Medicines Agency’s traditional-use registration is the clearest example, requiring documented long-standing use plus plausible pharmacology, explicitly without efficacy trials. Crape jasmine holds no such registration, monograph, or traditional-use recognition from any national or international regulatory body for pain, inflammation, or any other indication. It does not appear in the U.S. Pharmacopeia, the European Pharmacopoeia, or the WHO monographs on selected medicinal plants. This is not a technicality: it means there is no official minimum quality or identity standard a consumer product claiming to contain this plant is required to meet, on top of there being no dose, no human trial, and no established safety margin.

What Would Actually Settle This

A real human analgesic trial for a plant extract is a well-established design: a standardised, chemically characterised extract at a fixed dose, a validated pain-intensity scale (a visual analogue scale or numeric rating scale) with a defined clinically important difference, a placebo or active comparator arm, and blinding. None of that exists for crape jasmine in any preparation. The two whole-extract rodent studies above are the closest thing to a foundation such a trial could be built on — they at least specify a plant part, an extraction method and a dose — but they remain single, unreplicated, animal-only findings.

Back to Table of Contents

Evidence Ledger for This Page

  1. Conolidine as a non-opioid analgesic via ACKR3/CXCR7. Tier: rigorous, mechanistically confirmed preclinical drug-discovery science. About a synthesised molecule; not about the plant.
  2. Whole flower-extract anti-nociception (partly opioid-mediated). Tier: single real rodent study with mechanistic probing. Unreplicated; no human data; not the non-opioid story the plant is famous for.
  3. Gastroprotective/anti-ulcer activity. Tier: single real dose-responsive rodent study against a validated drug comparator.
  4. General anti-inflammatory activity (carrageenin paw model). Tier: older (1996) but real rodent finding, alongside an incidental sedative signal.
  5. Relative analgesic potency versus other traditional plants. Tier: weakest of four species tested in one small comparative study — a useful corrective against overstatement.
  6. Human efficacy or safety data for pain or inflammation, in any preparation. Tier: absent.

Practical Guidance

Back to Table of Contents

Key Research Papers

  1. Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC. Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nature Chemistry, 2011. Find on PubMed.
  2. Szpakowska M, Decker AM, Meyrath M, Palmer CB, Blough BE, Namjoshi OA, Chevigné A. The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7. Signal Transduction and Targeted Therapy, 2021. Find on PubMed.
  3. Edinoff AN, Patel AS, Baker MW, Lawson J, Wolcott C, Cornett EM, Sadegi K, Kaye AM, Kaye AD. Conolidine: a novel plant extract for chronic pain. Anesthesiology and Pain Medicine, 2021. Find on PubMed.
  4. Ali Khan MS, Misbah, Ahmed N, Arifuddin M, Rehman A, Ling MP. Indole alkaloids and anti-nociceptive mechanisms of Tabernaemontana divaricata (L.) R. Br. flower methanolic extract. Food and Chemical Toxicology, 2018. Find on PubMed.
  5. Ali Khan MS, Mat Jais AM, Afreen A. Prostaglandin analogous and antioxidant activity mediated gastroprotective action of Tabernaemontana divaricata (L.) R. Br. flower methanolic extract against chemically induced gastric ulcers in rats. BioMed Research International, 2013. Find on PubMed.
  6. Henriques AT, Melo AA, Moreno PR, Ene LL, Henriques JA, Schapoval EE. Ervatamia coronaria: chemical constituents and some pharmacological activities. Journal of Ethnopharmacology, 1996. Find on PubMed.
  7. Khan MA, Islam MT. Analgesic and cytotoxic activity of Acorus calamus L., Kigelia pinnata L., Mangifera indica L. and Tabernaemontana divaricata L. Journal of Pharmacy & Bioallied Sciences, 2012. Find on PubMed.
  8. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn S. Ethnobotany & ethnopharmacology of Tabernaemontana divaricata. Indian Journal of Medical Research, 2008. Find on PubMed.
  9. Naidoo CM, Naidoo Y, Dewir YH, Murthy HN, El-Hendawy S, Al-Suhaibani N. Major bioactive alkaloids and biological activities of Tabernaemontana species (Apocynaceae). Plants, 2021. Find on PubMed.
  10. Bhadane BS, Patil MP, Maheshwari VL, Patil RH. Ethnopharmacology, phytochemistry, and biotechnological advances of family Apocynaceae: a review. Phytotherapy Research, 2018. Find on PubMed.

Back to Table of Contents

Connections

Back to Table of Contents